Literature DB >> 7510307

Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization.

T Barni1, B G Vannelli, R Sadri, C Pupilli, P Ghiandi, M Rizzo, C Selli, M Serio, G Fiorelli.   

Abstract

It has been previously reported that 1) type I insulin-like growth factor (IGF) receptors are present in the human prostatic tissue; 2) IGF-I receptors are mainly localized in the epithelial cells; 3) IGF-I is a mitogen for prostatic epithelial cells in culture; and 4) IGF-binding proteins (IGFBPs) are released by these cells in the conditioned medium. To add information on the mechanism of IGF-I action in the human prostate, we studied the expression and cellular localization of mRNA encoding IGF-I and IGFBP-4 in human prostatic hyperplastic (BPH) tissue. Northern analysis of total RNA extracted from BPH tissues with cDNA probes containing the entire coding regions for IGF-I and IGFBP-4 documented the presence of multiple IGF-I mRNA transcripts with lengths of 7.5, 1.7, 1.3, and 1.1 kilobases and a single 2.1-kilobase transcript of IGFBP-4 mRNA. In situ hybridization with the cDNA probes used for Northern analysis and with cRNA probes synthesized from the respective cDNA demonstrated that IGF-I mRNA was only localized in the stromal cells, whereas IGFBP-4 mRNA was predominantly expressed by epithelial cells. In addition, immunoreactive IGF-I was measured in BPH tissue extracts after acidification and reverse phase chromatography. The mean (+/- SD) IGF-I content of six BPH tissues was 28.1 +/- 4.0 ng/g tissue. Our results suggest that in the human prostate, the locally secreted IGF-I exerts its principal biological effects with a paracrine mode of action and demonstrate that IGFBP-4 is mainly expressed by IGF-I target cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510307     DOI: 10.1210/jcem.78.3.7510307

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Endoglin regulates cancer-stromal cell interactions in prostate tumors.

Authors:  Diana Romero; Christine O'Neill; Aleksandra Terzic; Liangru Contois; Kira Young; Barbara A Conley; Raymond C Bergan; Peter C Brooks; Calvin P H Vary
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

Review 2.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 3.  Growth factors as mediators of androgen action during the development of the male urogenital tract.

Authors:  G R Cunha; B Foster; A Thomson; Y Sugimura; N Tanji; M Tsuji; N Terada; P W Finch; A A Donjacour
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).

Authors:  M Maggi; C Crescioli; A Morelli; E Colli; L Adorini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

5.  Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.

Authors:  Harvey J Murff; Christianne L Roumie; Robert A Greevy; Carlos G Grijalva; Adrianna H Hung; Xulei Liu; Marie R Griffin
Journal:  J Mens Health       Date:  2014-12-01       Impact factor: 0.537

6.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

7.  Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?

Authors:  Zongwei Wang; Aria F Olumi
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-08

Review 8.  The insulin-like growth factor system in the prostate.

Authors:  D M Peehl; P Cohen; R G Rosenfeld
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 9.  Dietary Carcinogens and DNA Adducts in Prostate Cancer.

Authors:  Medjda Bellamri; Robert J Turesky
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.